Tenecteplase treatment for minor ischemic strokes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the effectiveness of tenecteplase, a thrombolytic agent, in patients experiencing acute minor ischemic strokes with specific imaging criteria. Participants will be randomly assigned to receive either tenecteplase or standard medical treatment within 12 hours of symptom onset. The study aims to determine if tenecteplase can improve functional outcomes at 90 days, as measured by the Modified Rankin Scale. It is a multicenter, prospective, open-label, blinded-endpoint randomized controlled trial.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Age ≥ 18 years;
2. Onset-to-treatment time \< 4.5 h; onset time defined as "last known well" time;
3. Clinical diagnosis of minor ischemic stroke (NIHSS ≤ 5) with persistent unilateral limb weakness or speech symptoms, defined as a score of ≥1 on either the language item or a single limb item of the NIHSS;
4. Pre-stroke mRS 0-1;
5. Informed consent signed.

Exclusion Criteria

1. Planned or likely acute endovascular treatments before randomization;
2. NIHSS 1a \> 2;
3. Known allergic to rhTNK-tPA;
4. History of intracranial hemorrhage;
5. Severe head trauma or previous stroke within 3 months；
6. Intracranial or spinal surgery within 3 months;
7. Gastrointestinal or urinary tract hemorrhage within 3 weeks；
8. Major surgery within 2 weeks;
9. Arterial puncture at a non-compressible site within 1 week；
10. Intracranial tumors (excluding neuroectodermal tumors, e.g., meningiomas), large intracranial aneurysms, or arteriovenous malformations；
11. Intracranial hemorrhage, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, and subdural/epidural hematoma;
12. Active visceral bleeding;
13. Concomitantaortic arch dissection;
14. Acute bleeding tendency, including platelet count \<100×10⁹/L or other clinically significant conditions;
15. Uncontrolled hypertension after active antihypertensive treatment: systolic blood pressure \>180 mm Hg or diastolic \>100 mm Hg;
16. Blood glucose \< 2.8 or \> 22.2 mmol / L;
17. Prior anticoagulant therapy, such as oral warfarin, with an INR \>1.7 or PT \>15 seconds;
18. Use of heparin within 24 hours;
19. Use of thrombin inhibitors or factor Xa inhibitors within 48 hours;
20. Large cerebral infarction on head CT or MRI (infarction area \>1/3 of the middle cerebral artery territory);
21. Todd's paralysis after a seizure or other neurological/psychiatric disorders affecting cooperation;
22. Severe, uncontrolled infections (e.g., acute pericarditis, infective endocarditis, or acute pancreatitis);
23. Pregnant or breastfeeding women, or women unwilling to use effective contraception during the study period;
24. Participation in another clinical trial within 3 months prior to screening;
25. Other severe illnesses with a life expectancy of less than six months;
26. Deemed unsuitable for the study or at increased risk by the investigator's judgment.

Where it's running

• Beijing Tiantan Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Yongjun Wang, MD, PhD
• Email: yongjunwang@ncrcnd.org.cn
• Phone: 86-13911172565

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Risk prediction for stroke and cognitive decline in Moyamoya disease and Moyamoya syndrome

  A large multicenter study tests whether combining clinical data, imaging, lab and genetic information can predict who will have stroke or cognitive decline among people with Moyamoya.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality and 12 other locations · NCT07894107

• Predicting unruptured brain aneurysm rupture risk with blood pressure variability and 3D changes

  This study follows adults with unruptured intracranial aneurysms who are managed without surgery to see if blood pressure variability and 3D changes in the aneurysm can predict rupture risk using advanced AI.

  Recruiting Beijing Tiantan Hospital · Beijing · NCT07893574

• Ischemic preconditioning to reduce ischemic events in Moyamoya with standard care

  This study tests whether remote ischemic conditioning can lower stroke risk for adults with Moyamoya disease who are receiving standard medical care.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07889531

• Rapid CSF ctDNA Test and Treatment Monitoring for Primary CNS Lymphoma

  This study tests whether CSF circulating tumor DNA can quickly diagnose primary CNS lymphoma and monitor response to treatment in adults.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07851363

• Biobank Registry for Primary CNS Lymphoma in China

  This study will collect and register a long-term, multimodal biobank from adults with PCNSL to support future research, using patients with similar diagnoses as controls and healthy volunteers for comparison.

  Recruiting at 3 sites Beijing Tiantan Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07842835

• Zanubrutinib plus Lenalidomide for frail elderly with newly diagnosed PCNSL

  This study tests whether a combination of zanubrutinib and lenalidomide can help frail elderly patients with newly diagnosed primary CNS lymphoma.

  Recruiting Phase 2 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07839247

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.